期刊文献+

Efficacy and safety of the treatment: combination of benazepril/ lercanidipine vs. benazepril alone in patients with mild-to-moderate hypertension 被引量:2

Efficacy and safety of the treatment: combination of benazepril/ lercanidipine vs. benazepril alone in patients with mild-to-moderate hypertension
原文传递
导出
摘要 Background Combination therapy is an effective method to reduce the blood pressure (BP) for patients with hypertension.This study was performed to evaluate the efficacy and safety of benazepril/lercanidipine compared with benazepril alone in patients with mild-to-moderate hypertension.Methods One hundred and eighty-one patients with mild-to-moderate primary hypertension were assigned in this randomized,single-blind,parallel-group study and were randomly divided into group A (benazepril 10 mg/lercanidipine 10 mg) and group B (benazepril 10 mg) for 8 weeks.At 4 weeks,the dosage of Benazepril was titrated up to 20 mg if the diastolic blood pressure (DBP) remained ≥90 mmHg.BP control and side effects were evaluated at the end of 1,4 and 8 weeks.Results The baseline characteristics of the two groups were similar.The BP in both groups decreased from the baseline (P 〈0.05).At the end of 4 and 8 weeks,Benazepril/Lercanidipine produced greater BP reduction than Benazepril alone (P 〈0.05).The comparison of the rate of BP control for the benazepril/lercanidipine and benazepril groups at the end of 1,4,and 8 weeks were 41.2% vs.37.6% (P 〉0.05),67.1% vs.44.7% (P 〈0.05),and 71.8% vs.45.9% (P 〈0.05).There was no significant difference of side effects between the two groups.Conclusion The benazepril/lercanidipine combination is more effective in reducing BP than benazepril alone,while it does not increase the incidence of side effects. Background Combination therapy is an effective method to reduce the blood pressure (BP) for patients with hypertension.This study was performed to evaluate the efficacy and safety of benazepril/lercanidipine compared with benazepril alone in patients with mild-to-moderate hypertension.Methods One hundred and eighty-one patients with mild-to-moderate primary hypertension were assigned in this randomized,single-blind,parallel-group study and were randomly divided into group A (benazepril 10 mg/lercanidipine 10 mg) and group B (benazepril 10 mg) for 8 weeks.At 4 weeks,the dosage of Benazepril was titrated up to 20 mg if the diastolic blood pressure (DBP) remained ≥90 mmHg.BP control and side effects were evaluated at the end of 1,4 and 8 weeks.Results The baseline characteristics of the two groups were similar.The BP in both groups decreased from the baseline (P 〈0.05).At the end of 4 and 8 weeks,Benazepril/Lercanidipine produced greater BP reduction than Benazepril alone (P 〈0.05).The comparison of the rate of BP control for the benazepril/lercanidipine and benazepril groups at the end of 1,4,and 8 weeks were 41.2% vs.37.6% (P 〉0.05),67.1% vs.44.7% (P 〈0.05),and 71.8% vs.45.9% (P 〈0.05).There was no significant difference of side effects between the two groups.Conclusion The benazepril/lercanidipine combination is more effective in reducing BP than benazepril alone,while it does not increase the incidence of side effects.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2013年第12期2286-2290,共5页 中华医学杂志(英文版)
关键词 HYPERTENSION combination therapy BENAZEPRIL LERCANIDIPINE hypertension combination therapy benazepril lercanidipine
  • 相关文献

参考文献28

  • 1Collins OR, Peto R. Antihypertensive drug therapy: effects on stroke and coronary heart disease. In: Swales JD, ed. Textbook of Hypertension. Oxford, England: Blackwell Scientific Publications. 1994: 1156-1164.
  • 2Hansson L, Zanchetti A, Carruthers SG, Daholf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755-1762.
  • 3Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin-convertingenzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) Randomised Trial. Lancet 1999; 353: 611-616.
  • 4Sutton JM, Bagby SP. Non-traditional combination pharmacotherapy of hypertension. Cleve Clin J Med 1992; 59: 59-468.
  • 5Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187.
  • 6Frishman WH, Bryzinski BS, Coulson LR, DeQuattro VL, Vlachakis ND, Mroczek WJ, et al. A multifactorial trial design to assess combination therapy in hypertension: treatment with bisoprolol and hydrochlorothiazide. Arch Intern Med 1994; 154: 1461-1468.
  • 7Epstein M, Bakris G. Newer approaches to antihypertensive therapy: use of fixed-dose combination therapy. Arch Intern Med 1996; 156: 1969-1978.
  • 8Frishman WH, RAM CV, McMahon FG, Chrysant SG, Graff A, Kupiec JW, et al. Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: a randomized, double-blind, placebo-controlled, parallel group study. The Benazeprill Amlodipine Study Group. J Clin Pharmacol1995; 35: 1060-1066.
  • 9Frishman WH, Landau A, Cretkovic A. Combination drug therapy with calcium-channel blockers in the treatment of systemic hypertension. J Clin Pharmacol1993; 33: 752-755.
  • 10White WB, Viadero JJ, Lane TJ, Podesla S. Effects of combination therapy with captopril and nifedipine in severe or resistant hypertension. Clin Pharmacol Ther 1986; 39: 43-48.

同被引文献30

引证文献2

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部